Protocol Ledger

NCT04191096 · Phase III · TERMINATED

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Interventional Phase III clinical trial protocol NCT04191096 sponsored by Merck & Co. in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-02-12 Enrollment: 1,251 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04191096
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,251 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04191096
Protocol FieldVerified Registry Value
NCT IdentifierNCT04191096
Consolidated Lead SponsorMerck & Co.
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment1,251 participants (ACTUAL)
Registered Start Date2020-02-12
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI